Literature DB >> 1702216

Anti-Fas monoclonal antibody is cytocidal to human immunodeficiency virus-infected cells without augmenting viral replication.

N Kobayashi1, Y Hamamoto, N Yamamoto, A Ishii, M Yonehara, S Yonehara.   

Abstract

A cytotoxic monoclonal antibody (anti-Fas mAb) against the 200-kDa cell surface Fas antigen, which is associated with the tumor necrosis factor (TNF) receptor, was examined for its in vitro activity on human immunodeficiency virus (HIV)-infected cells. It was found that both TNF and anti-Fas mAb selectively killed the chronically HIV-infected cells. Uninfected cells were less sensitive to the antibody than those infected with HIV. When the cells were cultured in the presence of anti-Fas mAb immediately after the HIV infection, the spread of HIV-infected cells was suppressed by the antibody. TNF augmented both the synthesis of HIV-specific mRNA in HIV-infected cells and formation of multinucleated giant cells. In contrast, the anti-Fas mAb did not augment HIV replication or enhance the HIV-induced formation of syncytia. The results indicated that anti-Fas mAb mimicks the cytocidal action of TNF but does not augment HIV replication.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1702216      PMCID: PMC55224          DOI: 10.1073/pnas.87.24.9620

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Molecular structure of the human cytoplasmic beta-actin gene: interspecies homology of sequences in the introns.

Authors:  S Nakajima-Iijima; H Hamada; P Reddy; T Kakunaga
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

2.  Effect of interleukin-1 on the augmentation of human immunodeficiency virus gene expression.

Authors:  N Kobayashi; Y Hamamoto; Y Koyanagi; I S Chen; N Yamamoto
Journal:  Biochem Biophys Res Commun       Date:  1989-12-15       Impact factor: 3.575

3.  Augmentation of human immunodeficiency virus type 1 gene expression by tumor necrosis factor alpha.

Authors:  T Okamoto; T Matsuyama; S Mori; Y Hamamoto; N Kobayashi; N Yamamoto; S F Josephs; F Wong-Staal; K Shimotohno
Journal:  AIDS Res Hum Retroviruses       Date:  1989-04       Impact factor: 2.205

4.  Cachectin/tumour-necrosis-factor production by cancer patients.

Authors:  D Aderka; S Fisher; Y Levo; H Holtmann; T Hahn; D Wallach
Journal:  Lancet       Date:  1985-11-23       Impact factor: 79.321

5.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

6.  Antiviral effects of recombinant tumour necrosis factor in vitro.

Authors:  J Mestan; W Digel; S Mittnacht; H Hillen; D Blohm; A Möller; H Jacobsen; H Kirchner
Journal:  Nature       Date:  1986 Oct 30-Nov 5       Impact factor: 49.962

7.  Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome.

Authors:  J Lähdevirta; C P Maury; A M Teppo; H Repo
Journal:  Am J Med       Date:  1988-09       Impact factor: 4.965

8.  Biological activities of novel recombinant tumor necrosis factor having N-terminal amino acid sequences derived from cytotoxic factors produced by THP-1 cells.

Authors:  G Soma; Y Tsuji; Y Tanabe; K Noguchi; N Kitahara-Tanabe; T Gatanaga; H Inagawa; M Kawakami; D Mizuno
Journal:  J Biol Response Mod       Date:  1988-12

9.  Raised serum levels of tumour necrosis factor in parasitic infections.

Authors:  P Scuderi; K E Sterling; K S Lam; P R Finley; K J Ryan; C G Ray; E Petersen; D J Slymen; S E Salmon
Journal:  Lancet       Date:  1986-12-13       Impact factor: 79.321

10.  Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors.

Authors:  J Vilcek; V J Palombella; D Henriksen-DeStefano; C Swenson; R Feinman; M Hirai; M Tsujimoto
Journal:  J Exp Med       Date:  1986-03-01       Impact factor: 14.307

View more
  39 in total

1.  Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis.

Authors:  Julian J Lum; Oren J Cohen; Zilin Nie; Joel G Weaver; Timothy S Gomez; Xiao-Jian Yao; David Lynch; André A Pilon; Nanci Hawley; John E Kim; Zhaoxia Chen; Michael Montpetit; Jaime Sanchez-Dardon; Eric A Cohen; Andrew D Badley
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

Review 2.  Identification of genes involved in programmed cell death.

Authors:  G P Owens; J J Cohen
Journal:  Cancer Metastasis Rev       Date:  1992-09       Impact factor: 9.264

3.  Highly active anti-retroviral therapy (HAART) is associated with a lower level of CD4+ T cell apoptosis in HIV-infected patients.

Authors:  P M Roger; J P Breittmayer; C Arlotto; P Pugliese; C Pradier; G Bernard-Pomier; P Dellamonica; A Bernard
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

4.  Programmed cell death (apoptosis) in cord blood lymphocytes.

Authors:  S Aggarwal; A Gupta; S Nagata; S Gupta
Journal:  J Clin Immunol       Date:  1997-01       Impact factor: 8.317

5.  The 55-kD tumor necrosis factor receptor and CD95 independently signal murine hepatocyte apoptosis and subsequent liver failure.

Authors:  M Leist; F Gantner; G Künstle; I Bohlinger; G Tiegs; H Bluethmann; A Wendel
Journal:  Mol Med       Date:  1996-01       Impact factor: 6.354

6.  Apoptosis induced in CD4+ cells expressing gp160 of human immunodeficiency virus type 1.

Authors:  Y Y Lu; Y Koga; K Tanaka; M Sasaki; G Kimura; K Nomoto
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

Review 7.  Role of the Fas/Fas ligand apoptotic pathway in human immunodeficiency virus type 1 disease.

Authors:  D Kaplan; S Sieg
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

8.  Possible involvement of double-stranded RNA-activated protein kinase in cell death by influenza virus infection.

Authors:  T Takizawa; K Ohashi; Y Nakanishi
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

9.  Hepatic Fas antigen expression before and after interferon therapy in patients with chronic hepatitis C.

Authors:  M Okazaki; K Hino; K Fujii; N Kobayashi; K Okita
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

10.  Fas (CD95) expression on CD4+ T cells from HIV-infected patients increases with disease progression.

Authors:  S P Aries; B Schaaf; C Müller; R H Dennin; K Dalhoff
Journal:  J Mol Med (Berl)       Date:  1995-12       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.